Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker

Hypertension Research

Volumn 31, Issue 1, 2008, Pages 59-67

  Furumatsu, Yoshiyuki ^a,b   Nagasawa, Yasuyuki ^b   Tomida, Kodo ^a,b   Mikami, Satoshi ^a,b   Kaneko, Tetsuya ^a   Okada, Noriyuki ^a   Tsubakihara, Yoshiharu ^a   Imai, Enyu ^b   Shoji, Tatsuya ^a  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aldosterone; Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Proteinuria; Spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN TYPE 4; CREATININE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; LOSARTAN; POTASSIUM; POTASSIUM BINDING AGENT; SPIRONOLACTONE; TRICHLORMETHIAZIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYNCOPE; TREATMENT DURATION;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; COLLAGEN TYPE IV; DISEASE PROGRESSION; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM; PROSPECTIVE STUDIES; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; THIAZIDES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 40149090641     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.59     Document Type: Article

References (57)

1. Russo D, Pisani A, Balletta MM, et al: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33: 851-856.
2. Russo D, Minutolo R, Pisani A, et al: Coadministration of losartan and enalaptil exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18-25.
3. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124.
4. Okubo S, Niimura F, Nishimura H, et al: Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997; 99: 855-860.
5. Epstein M: Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001; 37: 677-688.
6. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B: Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33: 40-45.
7. Pitt B: "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995; 9: 145-149.
8. Sato A, Saruta T: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13-21.
9. Naruse M, Tanabe A, Sato A, et al: Aldosterone break-through during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33.
10. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C: Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999; 33: 981-986.
11. Harada E, Yoshimura M, Yasue H, et al: Aldosterone induces angiotensin-converting - enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001; 104: 137-139.
12. Sugiyama T, Yoshimoto T, Tsuchiya K, et al: Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 2005; 146: 3900-3906.
13. Epstein M: Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. Intern Med 2001; 40: 573-583.
14. Pitt B, Reichek N, Willenbrock R, et al: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.
15. White WB, Duprez D, St Hillaire R, et al: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021-1026.
16. Takeda Y: Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. Hypertens Res 2004; 27: 781-789.
17. Chrysostomou A, Becker G: Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-926.
18. Bianchi S, Bigazzi R, Campese VM: Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51.
19. Schjoedt KJ, Rossing K, Juhl TR, et al: Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836.
20. Bianchi S, Bigazzi R, Campese VM: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123.
21. Schjoedt KJ, Rossing K, Juhl TR, et al: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542.
22. Chrysostomou A, Pedagogos E, MacGregor L, Becker G: Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or wihtout an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262.
23. Pitt B, Zannad F, Remme WJ, et al, Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
24. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.
25. Bakris GL, Williams M, Dworkin L, et al: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
26. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D: The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13: 1682-1685.
27. Shimizu N, Miyashita H, Koide K, Yoshikawa J: Antipressor effect of spironolactone or thyazide diuretics for essential hypertension: double blind comparative study. Horumon To Rinsho 1977; 25: 167-174 (in Japanese).
28. Ginsberg JM, Chang BS, Matarese RA, Garella S: Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309: 1543-1546.
29. Schwab SJ, Christensen RL, Dougherty K, Klahr S: Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 1987; 147: 943-944.
30. Kawasaki T, Ueno M, Uezono K, et al: Average urinary excretion of sodium in 24 hours can be estimated from a spot-urine specimen. Jpn Circ J 1982; 46: 948-953.
31. Kawamura M, Kusano Y, Takahashi T, Owada M, Sugawara T: Effectiveness of a spot urine method in evaluating daily salt intake in hypertensive patients taking oral antihypertensive drugs. Hypertens Res 2006; 29: 397-402.
32. Obata K, Iwata K, Ichida T, et al: One step sandwich enzyme inummoassay for human type IV collagen using monoclonal antibodies. Clin Chim Acta 1989; 181: 293-303.
33. Donovan KL, Coles GA, Williams JD: An ELISA for the detection of type IV collagen in human urine - application to patients with glomerulonephritis. Kidney Int 1994; 46: 1431-1437.
34. Cameron JS, Blandford G: The simple assessment of selectivity in heavy proteinuria. Lancet 1966; 2: 242-247.
35. Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49.
36. Han KE, Kang YS, Han SY, et al: Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 2006; 70: 111-120.
37. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ: Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002; 87: 448-452.
38. Brown NJ, Vaughan DE, Fogo AB: The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol 2002; 22: 399-406.
39. Goumenos DS, Tsakas S, El Nahas AM, et al: Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant 2002; 17: 2145-2152.
40. Agarwal R, Siva S, Dunn SR, Sharma K: Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002; 39: 486-492.
41. Sato A, Suzuki Y, Saruta T: Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999; 22: 17-22.
42. Asai M, Monkawa T, Marumo T, et al: Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Hypertens Res 2004; 27: 971-978.
43. Sato A, Saruta T, Funder JW: Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006; 29: 211-216.
44. McKelvie RS, Yusuf S, Pericak D, et al: Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-1064.
45. Tang WH, Vagelos RH, Yee YG, et al: Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39: 70-78.
46. Price DA, Porter LE, Gordon M, et al: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382-2391.
47. Hollenberg NK, Price DA, Fisher ND, et al: Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003; 63: 172-178.
48. Watanabe H, Sanada H, Shigetomi S, Katoh T, Watanabe T: Urinary excretion of type IV collagen as a specific indicator of the progression of diabetic nephropathy. Nephron 2000; 86: 27-35.
49. Okonogi H, Nishimura M, Utsunomiya Y, et al: Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol 2001; 55: 357-364.
50. Tomino Y, Suzuki S, Azushima C, et al: Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. J Clin Lab Anal 2001; 15: 188-192.
51. Nishimura M, Sasaki T, Ohishi A, et al: Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy. Clin Nephrol 2001; 56: 96-103.
52. Goodfield NE, Newby DE, Ludlam CA, Flapan AD: Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-2985.
53. Fogari R, Zoppi A, Preti P, Fogari E, Malamani G, Mugellini A: Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens 2001; 14: 921-926.
54. Uzu T, Harada T, Namba T, et al: Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin A nephropathy treated with angiotensin II modulators. J Hypertens 2005; 23: 861-865.
55. Sato A, Saruta T: Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303-310.
56. Pitt B, Williams G, Remme W, et al: The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15: 79-87.
57. Juurlink DN, Mamdani MM, Lee DS, et al: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.